Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-02-22
2011-02-22
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
07893034
ABSTRACT:
Naturally occurring miRNAs that regulate human oncogenes and methods of use therof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions containing nucleic acids are administered to a patient in need of treatment or prophylaxis of at least one symptom or manifestation of cancer. In one embodiment, the compositions are administered in an effective amount to inhibit gene expression of one or more oncogenes. Methods for treatment or prevention of at least one symptom or manifestation of cancer are also described.
REFERENCES:
patent: 3832253 (1974-08-01), Di Palma et al.
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4452775 (1984-06-01), Kent
patent: 4667013 (1987-05-01), Reichle
patent: 4675189 (1987-06-01), Kent et al.
patent: 4748034 (1988-05-01), de Rham
patent: 5075109 (1991-12-01), Tice et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5239660 (1993-08-01), Ooi
patent: 5272071 (1993-12-01), Chappel
patent: 5378825 (1995-01-01), Cook et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5578461 (1996-11-01), Sherwin et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5614617 (1997-03-01), Cook et al.
patent: 5672697 (1997-09-01), Buhr et al.
patent: 5705629 (1998-01-01), Bhongle
patent: 5714606 (1998-02-01), Acevedo et al.
patent: 5736152 (1998-04-01), Dunn
patent: 5777092 (1998-07-01), Cook et al.
patent: 5858988 (1999-01-01), Wang
patent: 6919208 (2005-07-01), Levy et al.
patent: 2005/0186586 (2005-08-01), Zamore et al.
patent: 2005/0227256 (2005-10-01), Hutvagner et al.
patent: 2006/0141600 (2006-06-01), Joshua-Tor et al.
patent: WO 84/03564 (1984-09-01), None
patent: WO 91/06667 (1991-05-01), None
patent: WO 91/09955 (1991-07-01), None
patent: WO 92/20808 (1992-11-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 94/28122 (1994-12-01), None
patent: WO 2004/076622 (2004-02-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Crooke, S., Antisense REsearch and Application, Chapter 1, pp. 1-50 (Ed. by S. Crooke). Springer-Verlag (1998).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Branch, A., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Opalinska, J. B. et al., Nature REv., vol. 1, pp. 503-514 (2002).
Lagos-Quintana et al., RNA, vol. 9, pp. 175-179 (2003).
Crooke, S.T., Annu. Rev. Med., vol. 55, pp. 61-95 (2004).
Nguyen, E., et al., Curr. Opin. Molec. Therapeutics, vol. 10, No. 2, pp. 158-167 (2008).
Takamizawa et al., Cancer Res., vol. 64, pp. 3753-3756 (Jun. 2004).
McKay et al., EMBO J., vol. 5, No. 10, pp. 2617-2621 (1986).
Johnson et al., Nature, vol. 410, pp. 1111-1116 (2001).
Pulciani et al, Molecular & Cell. Biol., vol. 5, No. 10, pp. 2836-2841 (1985).
Abrahante, et al., “TheCaenorhabditis eleganshunchback-like gene lin-57/hbl-1 controls developmental time and is regulated by microRNAs”,Dev Cell, 4(5):625-637 (2003).
Ahrendt, et al., “Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung”,Cancer, 92:1525-1530 (2001).
Ambros, “Cell cycle-dependent sequencing of cell fate decisions inCaenorhabditis elegansvulva precursor cells”,Development, 126:1947-1956 (1999).
Ambros and Horvitz, “Heterochronic mutants of the nematodeCaenorhabditis elegans”, Science, 226:409-416 (1984).
Banerjee and Slack, “Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression”,Bioessays, 24(2):119-29 (2002).
Bartel, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function”,Cell, 116(2):281-97 (2004).
Beitel, et al., “Caenorhabditis elegansras gene let-60 acts as a switch in the pathway of vulval induction”,Nature, 348(6301):503-509 (1990).
Berset, et al., “Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 duringC. elegansvulval development”,Science, 291:1055-1058 (2001).
Brennecke, et al., “Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila”,Cell, 113(1):25-36 (2003).
Calin, et al., “Human microRNA gene are frequently located at fragile sites and genomic regions involved in cancers”,Proc Natl Acad Sci U S A, 101:2999-3004 (2004).
Calin, et al., “Frequent deletions and doenregulation of microRNA genesmiR15 andmiR16 at 13q14 in chronic lymphocytic leukemia”,Proc Natl Acad Sci U S A, 99(24):15524-9 (2002).
Capecchi, “Altering the genome by homologous recombination”,Science, 244:1288-1292 (1989).
Carmell, et al., “The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis”,Genes Dev., 16(21):2733-42 (2002).
Caudy, et al., “A micrococcal nuclease homologue in RNAi effector complexes”,Nature, 425(6956):411-4 (2003).
Ceol and Horvitz, “A new class ofC. eleganssynMuv genes implicates a Tip60/NuA4-like HAT complex as a negative regulator of Ras signaling”,Dev Cell, 6:563-576 (2004).
Chang, et al., “MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode”,Nature, 430(7001):785-9 (2004).
Chen, et al., “The developmental miRNA profiles of zebrafish as determined by small RNA cloning”,Genes Dev., 19(11):1288-93 (2005).
Chen, et al., “MicroRNAs Modulate HematopoieticLineage Differentiation”,Science, 303(5654):83-6 (2004).
Dent and Han, “Post-embryonic expression pattern ofC. elegans let-60 rasreporter constructs”,Mech Dev, 72:179-182 (1998).
Eisenmann and Kim, “Mechanism of activation of theCaenorhabditis elegansras homologue let-60 by a novel, temperature-sensitive, gain-of-function mutation”,Genetics, 146:553-565 (1997).
Feinbaum and Ambros, “The timing of lin-4 RNA accumulation controls the timing of postembryonic developmental events inCaenorhabditis elegans”, Dev Biol, 210(1):87-95 (1999).
Freemont, “The Ring finger. A novel protein sequence motif related to the zinc finger”,Ann. New York. Acad. Sci., 684:174-192 (1993).
Gauwerky, et al., “Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia”,Proc Natl Acad Sci U S A, 86(22):8867-71 (1989).
Giovanella, et al., Heterotransplantation of human malignant tumors in “nude” thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors,J. Natl. Can. Inst., 52:921-30 (1974).
Grishok, et al., “Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that controlC. elegansdevelopmental timing”,Cell, 106(1):23-34 (2001).
Groβshans, et al., “The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition inC. elegans”, Dev Cell, 8(3):321-30 (2005).
Haasch, et al., “T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC”,Cell Immunol, 217(1-2):78-86 (2002).
Hamilton and Baulcombe, “A species of small antisense RNA in posttranscriptional gene silencing in plants”,Science, 286(5441):950-2 (1999).
Han and Sternberg, “let-60, a gene that specifies cell fates duringC. elegansvulval inductio
Grosshans Helge
Johnson Steven M.
Slack Frank J.
Elrifi, Esq. Ivor R.
Miller Katherine J.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Yale University
Zara Jane
LandOfFree
Regulation of oncogenes by microRNAs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of oncogenes by microRNAs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of oncogenes by microRNAs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635010